Quantcast
Home > Quotes > XENE

Xenon Pharmaceuticals Inc. Common Shares (XENE) Quote & Summary Data

XENE 
$13.05
*  
0.25
1.88%
Get XENE Alerts
*Delayed - data as of Sep. 21, 2018  -  Find a broker to begin trading XENE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 13.45 / $ 12.55
Share Volume
204,365
50 Day Avg. Daily Volume
254,164
Previous Close
$ 13.30
52 Week High / Low
$ 15.922 / $ 2.10
Market Cap
268,332,651
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
204,365
50 Day Avg. Daily Volume:
254,164

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.54

Trading Range

The current last sale of $13.05 is 521.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.45 $ 15.922
 Low: $ 12.55 $ 2.10

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy and pain. To date, our pharmaceutical collaborations have generated in aggregate over $160.0 million in non-equity funding with the potential to provide us with future milestone payments, as well as royalties on product sales. Our current pharmaceutical partners include Genentech, a member of the Roche Group, and Merck & Co., Inc., or Merck (through its affiliate, Essex Chemie AG).  ... More ...  


Risk Grade

Where does XENE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.35
Open Date:
Sep. 21, 2018
Close Price:
$ 13.30
Close Date:
Sep. 21, 2018

Consensus Recommendation

Analyst Info